NVO peer analysis
Novo Nordisk (NVO) against its competitors: price, today's move, 1-year return and market value side by side.
NVO and its peers
| Company | Price | Today | 1-year return | Market cap |
|---|---|---|---|---|
| ABBV AbbVie | $294.88 | 0.15% | 26.43% | $521.23B |
| AMGN Amgen | $465.00 | -0.44% | 38.28% | $251.52B |
| AZN AstraZeneca | $185.06 | 0.37% | 5.53% | $287.00B |
| GSK GSK | $50.45 | -0.38% | 4.95% | $101.41B |
| JNJ Johnson & Johnson | $286.67 | 1.11% | 47.47% | $690.10B |
| LLY Eli Lilly | $1,439.99 | 0.89% | 41.48% | $1.35T |
| MRK Merck | $147.80 | 0.58% | 61.62% | $364.36B |
| PFE Pfizer | $28.93 | 0.34% | 11.82% | $164.88B |
| SNY Sanofi | $47.99 | -0.97% | -7.57% | $115.74B |
| NVO Novo Nordisk | $41.44 | 1.94% | -17.55% | $182.68B |
- NVO's peers: ABBV (AbbVie), AMGN (Amgen), AZN (AstraZeneca), GSK (GSK), JNJ (Johnson & Johnson), LLY (Eli Lilly), MRK (Merck), PFE (Pfizer).
Updated 2026-11-16 06:44 UTC